Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Have we a challenge of credibility in the invasive treatment of atrial fibrillation (AFIB)? The incidence of AFIB in the European Union (EU) is about 600,000 cases per year, while only 100,000 get an invasive treatment with a failure rate of close to 40%. Those that remain in AFIB need two times more hospitalizations and three times more re-hospitalizations. AFIB accounts for over 1% of the EU health care costs. Too many patients are not referred and the indication rates of cardiac ablation are inexplicably variable throughout the EU. A reflection is made on how electrocardiographic imaging (ECGI) can contribute to bringing the therapy to an advanced level by achieving a higher success rate, efficiently increasing access to ablation therapies, a better patient selection and therapy planning, personalization and follow up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jelectrocard.2018.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Impact of cryoballoon size adjustability on procedural and clinical outcomes.
Europace
September 2025
Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan.
Leveraging Implantable Cardiac Defibrillator Remote Transmissions to Predict the Occurrence of Atrial Fibrillation.
J Cardiovasc Electrophysiol
September 2025
Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, New York, USA.
Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist in patients, with the development of AF often preceding HF decompensation. We sought to evaluate whether daily remote monitoring of ICD parameters could predict AF occurrence using machine learning techniques in a real-world cohort.
Methods: Data from patients with primary prevention ICDs transmitted daily to the Northwell centralized remote monitoring center between 2012 and 2021 were extracted.
How Often is Multifocal Atrial Tachycardia Mistaken for Atrial Fibrillation in the Emergency Department?
Am J Med Sci
September 2025
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; Department of Internal Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
Objective: Multifocal atrial tachycardia (MAT), characterized by an irregularly irregular rhythm, is often regarded as a clinical imitator of atrial fibrillation (AF). We aimed to evaluate the prevalence of MAT misclassification as AF in the emergency department (ED) setting.
Methods: A retrospective analysis of 1,828 ECGs from patients discharged with AF diagnoses over five years.
Long-term Exposure to PM Components and Cardiovascular Admissions in Medicare Patients.
Environ Res
September 2025
Department of Environmental Health, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Background: Fine particulate matter (PM) has been previously linked to cardiovascular diseases (CVDs). PM is a mixture of components, each of which has its own toxicity profile which are not yet well understood. This study explores the relationship between long-term exposure to PM components and hospital admissions with CVDs in the Medicare population.
View Article and Find Full Text PDF